The FDA has been tasked with re-evaluating the safety of mifepristone after a flawed report claimed it has a high rate of serious complications.

Health and Human Services Secretary Robert F. Kennedy Jr. has tasked the Food and Drug Administration with conducting a safety review of mifepristone, a pill used in most U.S. abortions. Kennedy said this week that the review was warranted due to an “alarming” new report on serious adverse events released last month.

“Clearly it indicates that, at very least, the label should be changed,” he told Sen. Josh Hawley, R-Mo., at a Senate budget hearing on Wednesday. “I’ve asked Marty Makary, who’s the director of FDA, to do a complete review and to report back.”

The report in question, which was neither peer-reviewed nor published in a medical journal, claims to find a 22-times higher rate of serious complications from mifepristone than reported by the FDA. It calls on the agency to “further investigate the harm mifepristone causes to women” and “reconsider its approval altogether.”